## New Study Shows Medicaid Expansion Improved Treatment and Survival for Young Women with Breast Cancer

## The American Cancer Society led research to be presented at the 2023 ASCO annual meeting

In a new study by researchers at the American Cancer Society (ACS), Medicaid expansion under the Affordable Care Act was associated with an increased receipt of timely, guideline-based treatment and improved two-year survival among young women newly diagnosed with stage I-III breast cancer. The findings will be presented at this year's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6.

Using the National Cancer Database, researchers, led by <u>Dr. Xuesong Han</u>, scientific director, health services research at the American Cancer Society, and Dr. Xu Ji, reviewed data on more than 51,000 women ages 18-39 who had been diagnosed with breast cancer between 2011-2018 and compared data before and after Medicaid expansion and in expansion and non-expansion states. They examined how many women received guideline-based treatment such as surgery, or chemotherapy within 60 days of diagnosis as well as two-year survival rates.

According to study results, among all women diagnosed with stage I through stage III breast cancer, Medicaid expansion was associated with increased receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved two-year overall survival.

###

## **About the American Cancer Society**

The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 100 years, we have been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. We are committed to ensuring everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit cancer.org or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, Twitter, and Instagram.

For further information: anne.doerr@cancer.org